Parkinson’s disease: Is the initial treatment established?
- 37 Downloads
Recent studies have suggested that initial dopamine agonist therapy with pramipexole or ropinirole may slow the progression of Parkinson’s disease (PD) and also reduce the subsequent risk of levodopa motor complications. This presumed effect on PD progression, however, could be artifactual, resulting from the influence of chronic drug treatment on regulation of dopamine system proteins. With respect to levodopa motor complications, there is no dispute that pramipexole and ropinirole are effective in reducing levodopa dyskinesias and motor fluctuations; however, it is not clear that they must be started early, as opposed to initiation only after the levodopa complications develop. Levodopa therapy has numerous advantages that include greater efficacy, much lesser expense, simpler administration, and a lower frequency of hallucinosis and somnolence. Carbidopa/levodopa, pramipexole, and ropinirole are all appropriate first choices in the treatment of PD.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.Ahlskog JE, Muenter MD: Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16:448–458.The risk of either dyskinesias or motor fluctuations is approximately 40% after 4 to 6 years of levodopa treatment. However, these are incidence figures and do not take into account that these motor complications may be trivial or abolished with levodopa dose adjustments.PubMedCrossRefGoogle Scholar
- 8.Muenter MD, Ahlskog JE: Dopa dyskinesias and fluctuations are not related to dopa treatment duration. Ann Neurol 2000, 48:464.Google Scholar
- 11.Rascol O, Brooks D, Korczyn AD, et al.: A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000, 342:1484–1491.Clinical trials comparing initial dopamine agonist with levodopa therapy consistently have reported a lower subsequent frequency of dyskinesias and motor fluctuations with agonist treatment. Levodopa, however, has consistently been significantly more efficacious.PubMedCrossRefGoogle Scholar
- 12.Parkinson Study Group: A randomized controlled trial comparing the agonist pramipexole with levodopa as initial dopaminergic treatment for Parkinson’s disease. JAMA 2000, 284:1931–1938.Clinical trials comparing initial dopamine agonist with levodopa therapy consistently have reported a lower subsequent frequency of dyskinesias and motor fluctuations with agonist treatment. Levodopa, however, has consistently been significantly more efficacious.CrossRefGoogle Scholar
- 13.Whone AL, Remy P, Davis MR, et al.: The REAL-PET study: slower progression in early Parkinson’s disease treated with ropinirole compared with l-dopa. Neurology 2002, 58:A82-A83.Chronic ropinirole therapy resulted in a slower rate of decline of striatal 18F-dopamine compared with levodopa treatment.Google Scholar
- 14.Holloway RG, for the Parkinson Study Group: Pramipexole versus levodopa as initial treatment for Parkinson disease: a four-year randomized controlled trial. Neurology 2002, 58:A81-A82.Clinical trials comparing initial dopamine agonist with levodopa therapy consistently have reported a lower subsequent frequency of dyskinesias and motor fluctuations with agonist treatment. Levodopa, however, has consistently been significantly more efficacious.Google Scholar
- 15.Uitti RY, Ahlskog JE: Comparative review of dopamine receptor agonists in Parkinson’s disease. Cent Nerv Syst Drugs 1996, 5:369–388.Google Scholar
- 16.Parkinson Study Group: Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002, 287:1653–1661. Chronic pramipexole therapy was associated with a significantly slower rate of decline of striatal 123I-à-CIT uptake, as assessed by single photon emission computed tomography. Those treated with pramipexole alone had results similar to those who supplemented their pramipexole treatment with levodopa. 123I-β-CIT binds to the dopamine transporter, a biomarker of dopaminergic neurons.CrossRefGoogle Scholar
- 17.Kimmel HL, Joyce AR, Carroll FI, Kuhar MJ: Dopamine D1 and D2 receptors influence dopamine transporter synthesis and degradation in the rat. J Pharmacol Exp Ther 2001, 298:129–140.Dopamine transporter is a highly regulated protein with turnover influenced by dopamine agonist and levodopa administration.PubMedGoogle Scholar
- 27.Guttman M, Stewart D, Hussey D, et al.: Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001, 56:1559–1564.Levodopa and pramipexole differentially affected striatal 123I-à-CIT single photon emission computed tomography outcomes in a 6-week trial, suggesting a pharmacologic effect on dopamine transporter regulation.PubMedGoogle Scholar
- 33.Locatelli S, Lutjohann D, Schmidt HH, et al.: Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia. Evidence that simvastatin affects cholesterol metablism in the human brain. Arch Neurol 2002, 59:213–216.PubMedCrossRefGoogle Scholar
- 37.Boomsma F, Meerwaldt JD, Man in’t Veld AJ, et al.: Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-Omethyl-dopa. J Neurol 1989, 236:223–230.PubMedCrossRefGoogle Scholar